Akums Drugs and Pharmaceuticals Ltd — earnings calls

Akums reported FY26 revenue of Rs 4,359 crore, up 5.8%, with adjusted EBITDA of Rs 522 crore, up 13.3%, and adjusted EBITDA margin at 12% versus 11.2% in FY25. CDMO delivered double-digit volume growth driven by existing customers, while the API and international branded formulation businesses remained weak through the year with trade generics turning EBITDA positive in Q4. Management discussed progress on European GMP accreditation, the Zambia partnership, an EU contract, and capacity expansion across injectables, Penem and Baddi facilities.